The unparalleled bone and heart benefits of vitamin K2 MK-7 have opened doors to mass market consumers. More and more K2 products are being launched, with companies and marketers looking to gain first-mover advantage.Join Kappa Bioscience and a panel of industry experts who will discuss and answer questions about launching successful K2 products.The roundtable discussion and Q&A will cover:K2 science Market opportunity Commercial risksFormulationGalenicsStability and qualityAnalysisK2 is ready for mass markets. Join us to learn how to profit from the enormous potential of vitamin K2 MK-7.
Orkla Care A/S
Dr. Juergen Wolf
K2 MedicalCare GmbH
President & CEO
Executive VP of Nutraceuticals
Chemroy Canada Inc.
Vice President of Sales
Business Development Manager Consumer Health & Nutrition
Business Manager NSW, Food & Pharmaceutical
ALS Pharmaceutical Australia
Invenire Market Intelligence Oy